Filing Details

Accession Number:
0000947871-22-000722
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-24 17:39:05
Reporting Period:
2022-06-22
Accepted Time:
2022-06-24 17:39:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1835579 Ikena Oncology Inc. IKNA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022-4629
Yes No No No
1682115 Orbimed Capital Gp Vi Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
1808744 Orbimed Genesis Gp Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-06-22 66,806 $3.55 1,912,678 No 4 P Indirect See Footnotes
Common Stock Disposition 2022-06-23 23,419 $3.71 1,936,097 No 4 P Indirect See Footnotes
Common Stock Disposition 2022-06-24 65,965 $4.37 2,002,062 No 4 P Indirect See Footnotes
Common Stock Disposition 2022-06-24 96,035 $5.37 2,098,097 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 91,014 Indirect See Footnotes
Non-Voting Common Stock 5,429,023 Indirect See Footnotes
Non-Voting Common Stock 157,288 Indirect See Footnotes
Footnotes
  1. These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $3.53 to $3.68. The price reported reflects the weighted average purchase price. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the ranges set forth in this footnote.
  2. These Shares were purchased in a block at a price of $3.71.
  3. These Shares were purchased in a block at a price of $4.37.
  4. These Shares were purchased in a block at a price of $5.37.
  5. Each share of Non-Voting Common Stock is convertible into one Share at any time at the option of the holder without payment or additional consideration, subject to a 9.9% beneficial ownership limitation that may be increased or decreased by the holder upon 61 days' notice to the Issuer.
  6. The Shares are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VI.
  7. The Shares are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.
  8. This report on Form 4 is jointly filed by OrbiMed Advisors, GP VI, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, David P. Bonita ("Bonita"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Bonita is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.